DRD5 and type 2 diabetes mellitus: Though not statistically significant after adjustment for multiple comparisons, some enlightening pathways were identified in hypo-DMRs (Fig. 3B, red bar), including “cAMP signaling pathway” (ATP2B3/DRD5), “type II diabetes mellitus” (PRKCD), “cholesterol metabolism” (OSBPL5), “aldosterone synthesis and secretion” (ATP2B3), “insulin resistance” (PRKCD).